Male Breast Reduction in Missouri
Male Breast Reduction in Missouri section, includes general infrmation about Male Breast Reduction Procedure, Male Breast Reduction Missouri Local News, Male Breast Reduction Missouri Surgeon Locator and other Male Breast Reduction related material.
Male Breast Reduction Procedure
Breasts in males are called genycomastia, a Greek word meaning "breasts looking similar to women's". 40-60% of men have breasts; many conditions can cause this phenomenon like medication and medical problems (alcohol use, marihuana and steroids), but in most of the cases the reason is not known. It can damage self-confidence and self esteem, therefore breast reduction can help.
The ideal candidates for the operation are men with genicomastia for at least a year long who have developed chest muscles and elastic skin. The surgery is not recommended for overweight men who can't loose weight using diet and exercise.
In case of extra breast tissue the surgeon will remove it through an invisible cut around the nipple or below the breast fold. Sometimes extra fat also removed using this method; the canula used for suction of the fat is inserted through the cut already made. When there is extra skin needs to be removed, the procedure may leave bigger scars.
If the extra tissue is fat, liposuction is performed. The cuts, 5-7 millimeters long, are made at the margins of the breast, from below and from the side. Sometimes small cut is made around the nipple. You may feel a vibration sensation, but no pain, if the procedure is done using local anesthetics. In extreme cases when there is large amounts of fat and tissue extracted, the extra skin needs to be removed, then a drainage tube usually left to prevent fluid collection.
Finally, incisions are closed and pressure bandages are placed.
Every operation has its risks. The risks include infection, bleeding, fluid collection, breast asymmetry (that needs to be corrected in additional surgery), scars, nipple distortion and permanent color changes of the skin.
After the surgery you may feel uncomfortable, regardless of the technique used. It can be treated with painkillers. Swelling and hemorrhage may appear in the area, to reduce the swelling you'll be instructed to wear a tight bandage around the chest for several weeks day and night. The breast will reach their final size in 3 month or so. You'll be able to go back to work after a week or two. It is advised to restrain from sexual activity or physical efforts for at least 2 weeks, and any activity that may harm the chest for a month. It's important to avoid sunlight to your chest for 6 month to prevent color changes in the breast
Other Male Breast Reduction Procedures
All Breast Procedures
Male Breast Reduction Missouri (current)
Male Breast Reduction Missouri Breast Lift
Male Breast Reduction Missouri Breast Implants
Male Breast Reduction Missouri Implant Removal
Male Breast Reduction Missouri Armpit Incision
More Missouri info...
Missouri Get out This article is an outline and needs more content. It has a template, but there is not enough information present. Please plunge forward and help it grow!
Missouri Understand According to William Least Heat Moon, in Blue Highways, St. Louis is the last Eastern city and Kansas City is the first Western city.
Missouri is known as the "Show Me State". What that means is a person from Missouri will not believe unless they are shown. The slogan is not an official one, but it does appear on the license plates. It is an endearing statement that people from Missouri say, "I'm from Missouri, you have to Show Me!".
Male Breast ReductionLatest Forum Posts...
- hi, are there any non-surgical procedures that can be done to reduce my man-breasts? it's kinda annoying and embarrassing.
Plastic Surgery News...
- Abstract The use of a new technique for harvesting of the pectoralis major muscle in the reconstruction of locally recurrent breast
cancer is presented and illustrated in two cases. This technique provides the versatility of the myocutaneous flap but avoids
the significant donor site morbidity and unreliability of the skin paddle.
Content Type Journal ArticleCategory Case ReportDOI 10.1007/s00238-007-0212-0Authors
Reza S. Nassab, Nottingham University Hospitals, Nottingham City Hospital Department of Plastic Surgery Nottingham UKJason Neil-Dwyer, Nottingham University Hospitals, Nottingham City Hospital Department of Plastic Surgery Nottingham UKKristjen S. Asgeirsson, Nottingham University Hospitals, Nottingham City Hospital Department of Plastic Surgery Nottingham UKA. Graeme B. Perks, Nottingham University Hospitals, Nottingham City Hospital Department of Plastic Surgery Nottingham UK
Journal European Journal of Plastic SurgeryOnline ISSN 1435-0130Print ISSN 0930-343X (Source: European Journal of Plastic Surgery)
Context No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers.
Objective To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes.
Design, Setting, and Participants Double-blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America (enrollment August 2003-March 2006) in 543 patients with coronary disease and type 2 diabetes.
Interventions A total of 543 patients underwent coronary intravascular ultrasonography and were randomized to receive glimepiride, 1 to 4 mg, or pioglitazone, 15 to 45 mg, for 18 months with titration to maximum dosage, if tolerated. Atherosclerosis progression was measured by repeat intravascular ultrasonography examination in 360 patients at study completion.
Main Outcome Measure Change in percent atheroma volume (PAV) from baseline to study completion.
Results Least squares mean PAV increased 0.73% (95% CI, 0.33% to 1.12%) with glimepiride and decreased 0.16% (95% CI, –0.57% to 0.25%) with pioglitazone(P = .002). An alternative analysis imputing values for noncompleters based on baseline characteristics showed an increase in PAV of 0.64% (95% CI, 0.23% to 1.05%) for glimepiride and a decrease of 0.06% (–0.47% to 0.35%) for pioglitazone (between-group P = .02). Mean (SD) baseline HbA1c levels were 7.4% (1.0%) in both groups and declined during treatment an average 0.55% (95% CI, –0.68% to –0.42%) with pioglitazone and 0.36% (95% CI, –0.48% to –0.24%) with glimepiride (between-group P = .03). In the pioglitazone group, compared with glimepiride, high-density lipoprotein levels increased 5.7 mg/dL (95% CI, 4.4 to 7.0 mg/dL; 16.0%) vs 0.9 mg/dL (95% CI, –0.3 to 2.1 mg/dL; 4.1%), and median triglyceride levels decreased 16.3 mg/dL (95% CI, –27.7 to –11.0 mg/dL; 15.3%) vs an increase of 3.3 mg/dL (95% CI, –10.7 to 11.7 mg/dL; 0.6%) (P < .001 for both comparisons). Median fasting insulin levels decreased with pioglitazone and increased with glimepiride (P < .001). Hypoglycemia was more common in the glimepiride group and edema, fractures, and decreased hemoglobin levels occurred more frequently in the pioglitazone group.
Conclusion In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride.
Trial Registration clinicaltrials.gov Identifier: NCT00225277
Published online March 31, 2008 (doi:10.1001/jama.299.13.1561).